NEW YORK, Feb. 2, 2017 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Stemline Therapeutics, Inc. ("Stemline" or the "Company") (NASDAQ: STML). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/stml.
The investigation concerns whether Stemline and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On January 19, 2017, Stemline announced its proposed public offering of common stock and on the next day, January 20, 2017, Stemline set the pricing of the public offering of 4.5 million shares at $10.00 per share, with projected gross proceeds of $45 million. On February 2, 2017, TheStreet narrated that on January 18, 2017 a cancer patient in a clinical trial died from a severe side effect tied to Stemline's drug SL-401 and this information was not disclosed to investors who bought into Stemline's public offering. Following this news, Stemline stock dropped during intraday trading on February 2, 2017.
If you are aware of any facts relating to this investigation, or purchased Stemline shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/stml. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-stemline-therapeutics-inc-stml-300401438.html
SOURCE Bronstein, Gewirtz & Grossman, LLC